Drug Profile
Research programme: inhaled broad-spectrum antibacterial therapy - National Resilience
Alternative Names: Gentamicin dry-powder inhalation - National Resilience; NanoGENTLatest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Nanotherapeutics
- Developer National Resilience
- Class
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pneumonic plague; Respiratory tract infections; Tuberculosis; Tularaemia
Most Recent Events
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumonic-plague in USA (Inhalation, Powder)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-infections in USA (Inhalation, Powder)